My complaint is the non release of NR's regarding the science...when it's good information it inspires buyers to either start/continue to buy more. These releases don't damage licensing agreements. We've had many other public NR's in the past. A higher public share price will inform bidders that they will have to pay more than a languishing price that has neither volume or movement up for months.

I'm interested in tracking down the IB as they are a subsiderary now of another bank that the team is all now in Scottsdale.